Skip to main content
An official website of the United States government
Grant Details

Grant Number: 5R01CA078828-03 Interpret this number
Primary Investigator: Reid, Brian
Organization: Fred Hutchinson Cancer Research Center
Project Title: Epidemiology of P16 Inactivation in Barretts Esophagus
Fiscal Year: 2000


DESCRIPTION: Esophageal adenocarcinoma is one of the most rapidly increasing cancers in the United States. Most patients with this cancer present when the tumor is advanced; over 90% will die of their disease. Persons with metaplastic Barrett's esophagus are at high risk of developing this cancer, estimated at 30 - 40 times that of the general population. The neoplastic progression that can be observed in serial esophageal biopsies of persons with Barrett's esophagus involves the development of genetic instability and the accumulation of multiple genetic and cell cycle abnormalities. Inactivation of the p16 tumor suppressor gene occurs relatively early during progression and is detected in approximately 85 percent of patients who develop aneuploidy and cancer. The mechanisms of p16 inactivation involves 9p21 LOH of one allele and either mutation or promoter hypermethylation of the other p16 allele. The Specific Aims of this project are to: 1) determine the prevalence of p16 abnormalities, including p16 mutation, p16 promoter hypermethylation and 9p21 LOH at each stage of histologic progression in patients with Barrett's esophagus; and 2) investigate the association of each abnormality with specific environmental exposures or host factors that are believed to increase risk for esophageal adenocarcinoma. These will include age, gender, tobacco use, alcohol use, body mass index, diet, serum micronutrient levels and use of various medications. An existing cohort of patients who represent all stages of disease and for whom interviews, anthropometry, serum, and biopsies are available will be used for these investigations. DNA content and Ki67/DNA content multiparameter flow cytometry will be used to analyze and to purify cell populations from endoscopic biopsies. The flow-purified samples will then be used to detect p16 mutations, p16 promoter hypermethylation and 9p21 LOH. LOH will be determined by automated genotyping using fluoresce-labeled polymorphic markers within and flanking the p16 locus on 9p21. Mutations in p16 will be detected using PCR template and fluorescent automated sequencing. Promoter hypermethylation will be assayed using methylation-specific PCR and whole genome amplification according to our published protocols. Statistical approaches will include contingency table analysis, logistic regression and generalized linear mixed models. These results will lead to a better understanding of the relationships between etiologic factors and molecular mechanisms for inactivating a human tumor suppressor gene in a highly fatal cancer in vivo.


p16 mutation spectrum in the premalignant condition Barrett's esophagus.
Authors: Paulson T.G. , Galipeau P.C. , Xu L. , Kissel H.D. , Li X. , Blount P.L. , Sanchez C.A. , Odze R.D. , Reid B.J. .
Source: PloS one, 2008; 3(11), p. e3809.
EPub date: 2008-11-27.
PMID: 19043591
Related Citations

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Authors: Galipeau P.C. , Li X. , Blount P.L. , Maley C.C. , Sanchez C.A. , Odze R.D. , Ayub K. , Rabinovitch P.S. , Vaughan T.L. , Reid B.J. .
Source: PLoS medicine, 2007 Feb; 4(2), p. e67.
PMID: 17326708
Related Citations

Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Authors: Chao D.L. , Maley C.C. , Wu X. , Farrow D.C. , Galipeau P.C. , Sanchez C.A. , Paulson T.G. , Rabinovitch P.S. , Reid B.J. , Spitz M.R. , et al. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006 Oct; 15(10), p. 1935-40.
PMID: 17035402
Related Citations

Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
Authors: Vaughan T.L. , Kristal A.R. , Blount P.L. , Levine D.S. , Galipeau P.C. , Prevo L.J. , Sanchez C.A. , Rabinovitch P.S. , Reid B.J. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2002 Aug; 11(8), p. 745-52.
PMID: 12163328
Related Citations

p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
Authors: Wong D.J. , Paulson T.G. , Prevo L.J. , Galipeau P.C. , Longton G. , Blount P.L. , Reid B.J. .
Source: Cancer research, 2001-11-15; 61(22), p. 8284-9.
PMID: 11719461
Related Citations

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Authors: Galipeau P.C. , Prevo L.J. , Sanchez C.A. , Longton G.M. , Reid B.J. .
Source: Journal of the National Cancer Institute, 1999-12-15; 91(24), p. 2087-95.
PMID: 10601379
Related Citations

Back to Top